Dalton Transactions

Introduction
In the treatment of acute iron (Fe) overload disorders, the administration of Fe chelating ligands is essential. 1, 2 In humans, intestinal Fe absorption is tightly regulated 3 and when Fe levels are adequate, further Fe uptake is inhibited. In cases where severe Fe overload occurs, commonly through necessary blood transfusions in the treatment of anaemias such as β-thalassemia, Fe overload becomes acute, as humans have no mechanism for actively excreting excess Fe. Failure to remove excess Fe leads to its accumulation in vital organs such as the heart and liver, and if left untreated, leads to irreversible organ damage and death.
Few Fe chelators have been successful in treating Fe overload in the clinic. Desferrioxamine (DFO; Chart 1) was for many years the only drug approved worldwide for the treatment of Fe overload. Its widespread use continues today, despite its major drawback of not being orally active. 4 In fact, DFO must be administered by long and frequent periods of subcutaneous infusion (12-24 h per day, 5-6 times a week). In 2005, the triazole deferasirox (Exjade®, Chart 1), [5] [6] [7] [8] was approved by the US Food and Drug Administration (FDA) for oral administration in the treatment of Fe overload and was the first drug of its type to be approved worldwide. However, possible side effects such as renal and liver damage and gastrointestinal haemorrhage in some patients were added as warnings to the packaging of this drug in 2010. ‡
The hydroxypyridinones (such as deferiprone also known as L1 and more recently Ferriprox®) emerged in the 1980s 9 and also offered the hope of oral activity, but controversy surrounding their efficacy and toxicity 10, 11 hampered drug development over the years. In 2011, the FDA finally granted approval for the 'second line' use of deferiprone as an orally administered drug in the treatment of Fe overload, § although there are still unresolved questions over its efficacy. Notably, the most promising clinical results with deferiprone have been obtained when it is co-administered with DFO where it appears to be effective against Fe loading in heart tissue. 12 The tridentate 2-pyridinecarbaldehyde isonicotinoyl hydrazone (HPCIH) family of Fe chelators (Chart 1) have shown promise as alternatives to existing compounds for the treatment of Fe overload. [13] [14] [15] [16] Investigations by our laboratories have shown that they form stable Fe II complexes, in contrast to the Fe III complexes formed by DFO, deferiprone and deferasirox. 1, 2, 4 Subsequent studies have shown that substitutions to the C-atom adjacent to the pyridyl ring lead to a marked change in biological activity, for example the HPCIH analogues based on 2-acetylpyridine (HAPIH series) 17 or di-2-pyridyl ketone (HPKIH analogues) 18 exhibit significant cytotoxicity in contrast to the benign HPCIH chelators. 16 Although deleterious for the treatment of chronic Fe overload (where chelators must be administered lifelong), cytotoxic Fe chelators may prove to be a novel and effective method in cancer therapy. [19] [20] [21] [22] [23] [24] [25] [26] Of interest, a significant increase in cytotoxicity and activity against neoplastic cells was found by substitution of the O-donor of the HPKIH and HAPIH hydrazones with an S-atom leading to the thiohydrazone (HPKTBH) 27 and thiosemicarbazone (HDp44mT) [28] [29] [30] families of chelators (Chart 1).
In the current investigation, we have assessed a series of dithiocarbazate Schiff base analogues (Chart 2) in their reactions with Fe. The ligands share the same NNS, tridentate donor set as the HDp44mT and HPKTBH analogues, but the terminal substituent is a mercaptomethyl or mercaptobenzyl group rather than an amine or aromatic ring. Dithiocarbazate Schiff bases are well described and a number of transition metal complexes are known [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] and these compounds have shown a wide spectrum of biological activity. Little is known about the Fe coordination chemistry of these dithiocarbazate Schiff base ligands 42, 43 and given the resemblance to the highly active thiosemicarbazone Fe chelators we have studied previously, 21, [28] [29] [30] this was the focus of the current work. Of particular interest are the relationships between chelator structure, redox properties of the Fe complex and the biological activity (including anti-proliferative efficacy). Modification of the substituents adjacent to the donor group is known to have a marked effect on redox potentials in compounds from the heterocyclic thiosemicarbazone [28] [29] [30] and hydrazone [16] [17] [18] series due to extended conjugation along the ligand backbone. Replacement of the terminal amino group with a thioether brings about both differences in inductive and resonance effects, which then are communicated to the coordinated metal ion. In this contribution, we investigate the Fe coordination chemistry of these dithiocarbazate ligands, their effectiveness at mobilising intracellular Fe and their anti-proliferative activity.
Experimental Safety note
Perchlorate salts are potentially explosive. Although we experienced no problems with the compounds described below they should never be heated in the solid state or scraped from sintered glass frits.
Reagents
S-Methyldithiocarbazate, 44 and S-benzyldithiocarbazate 45 were prepared according to literature syntheses. All other reagents were obtained commercially and used without further purification.
Free ligand syntheses 2-Acetylpyridine S-methyldithiocarbazate (HAPSMC). A suspension of S-methyl dithiocarbazate (6.11 g, 0.05 mol) in 75 mL of isopropanol was heated until it dissolved. This mixture was cooled to room temperature then filtered and the residue was washed with isopropyl alcohol then discarded. The filtrate was treated with 2-acetylpyridine (6.05 g, 0.05 mol) added dropwise. The mixture was stirred for 24 h at room temperature. The resulting yellow precipitate was filtered off, washed with isopropanol and recrystallised from ethanol to give a yellow crystalline product. Yield (7.3 g, 65%). Microanalysis found C, 48.1; H, 5.0; N, 18.8%; Calculated for C 9 H 11 N 3 S 2 : C, 48.0; H, 4.9; N, 18.7%. IR: ν (cm −1 ); 3144m, 2913w, 2114w, 1665w, 1615w, 1568m, 1562m, 1484m, 1460s, 1428s, 1366m, 1336m, 1254vs, 1144w, 115w, 1060vs, 1045m, 990w, 949vs, 886w, 774vs, 734vs, 678m, 642s, 620w, and 562m. 1 
2-Pyridinecarbaldehyde S-methyldithiocarbazate (HPCSMC).
S-Methyldithiocarbazate (6.11 g, 0.05 mol) was suspended in isopropanol (75 mL) and refluxed until it dissolved. The solution was allowed to cool to room temperature and the residue was filtered off, washed with isopropyl alcohol and discarded. The filtrate was treated with 2-pyridinecarbaldehyde (5.35 g, 0.05 mol) added drop-wise and the mixture was stirred for 24 h at room temperature. Then the resultant pale yellow precipitate was filtered, washed with isopropanol then recrystallised from ethanol to give pale yellow crystals. Yield (7.08 g, 67% 4 mmol) was dissolved in 15 mL of hot ethanol and then triethylamine (0.617 mL, 4.4 mmol) was added. Solid Fe(ClO 4 ) 3 ·6H 2 O (1.025 g, 2.2 mmol) was added directly to the basic ligand solution with stirring and the mixture was gently refluxed for 30 min. After cooling to room temperature, the resulting solid was filtered off and washed with ethanol (10 mL), followed by diethyl ether (10 mL). It was then dried in a vacuum desiccator and recrystallised from ethanol to give dark brown powder. Yield [Fe III (APSBC) 2 ](ClO 4 ). HAPSBC (0.7 g, 2.3 mmol) was dissolved in 30 mL of hot ethanol and Fe(ClO 4 ) 3 ·6H 2 O (0.54 g, 1.2 mmol) was added directly to the solution. Et 3 N (0.32 mL, 2.3 mmol) was added and the dark brown mixture was refluxed for 30 min. The reaction mixture was filtered while hot to obtain an initial crop of the desired product. The filtrate was allowed to cool at room temperature, and was then put in the refrigerator overnight. The brown precipitate was collected by vacuum filtration and washed with ethanol and diethyl ether to give a second crop. Total yield (0.62 g, 70%). Microanalysis C, 47.6; H, 3.7; N, 11.1%; Calculated for C 30 4 mmol) was dissolved in 300 mL of hot ethanol and then triethylamine (0.34 mL, 2.4 mmol) was added. Solid Fe(ClO 4 ) 3 ·6H 2 O (0.54 g, 1.2 mmol) was added to the basic ligand solution with stirring and the mixture was gently refluxed for 1 h. The reaction mixture was cooled to room temperature and the resulting crude dark brown solid containing a mixture of compounds was filtered off, washed with 10 mL of ethanol followed by 10 mL of diethyl ether. A column of dry silica (100 × 32 mm diameter, Scharlau or Merck Silica gel 60, 230-400 mesh) was prepared. The crude product (0.3 g) was dissolved in CH 3 CN (∼50 mL) and adsorbed onto Celite (∼1.3 g) by evaporation to dryness on a rotary evaporator at room temperature (see Safety Note). The resulting solids were packed dry onto the column which was tapped gently to remove air pockets. The column was eluted with a step-wise gradient of CH 3 CN-DCM starting with 0.1% CH 3 [Fe III (PCSMC) 2 ](ClO 4 ). HPCSMC (1 g, 4.7 mmol) was dissolved in 75 mL of hot ethanol and solid Fe(ClO 4 ) 3 ·6H 2 O (0.54 g, 2.4 mmol) was added directly to the solution. Triethylamine (0.66 mL, 4.7 mmol) was added to the dark brown mixture which was gently refluxed for 30 min. The reaction mixture was filtered while still hot to obtain an initial crop of dark brown compound. The filtrate was allowed to cool at room temperature and then refrigerated overnight. A second crop was obtained by vacuum filtration and was washed with ethanol and diethyl ether. Attempts to recrystallise the complex were unsuccessful. Column chromatography (as described in the previous synthesis) enabled separation of [ [Fe III (PCSMC)(PSMC)]·2Me 2 CO·4H 2 O. HPCSMC (1 g, 4.7 mmol) was dissolved in 100 mL of hot ethanol and then triethylamine (0.66 mL, 4.7 mmol) was added to the solution.
Solid Fe(ClO 4 ) 3 ·6H 2 O (1.08 g, 2.41 mmol) was added to the basic ligand solution with stirring and the mixture was gently refluxed for 1 h. On cooling to room temperature the resulting crude dark brown solid was filtered off and washed with 10 mL of ethanol followed by 10 mL of diethyl ether. Column chromatography on silica (see previous synthesis) was carried out using a solvent gradient of CH 3 
Physical methods
UV-vis spectra were recorded on a Perkin Elmer Lambda 40 spectrophotometer. Solutions were analysed immediately before any redox reactions occurred. This was particularly important for the Fe II complexes which slowly oxidised in aerated solutions. IR spectra were recorded as undiluted solids on a Perkin Elmer 1600 FTIR spectrometer in attenuated total reflectance mode. NMR spectra were acquired on a Bruker Avance 300 MHz spectrometer and all resonances were given relative to tetramethylsilane (δ = 0 ppm). Cyclic voltammetry was recorded with a BAS100B/W potentiostat employing a glassy carbon working electrode, Pt wire counter and Ag-AgCl reference electrode. The solvent was MeCN-H 2 O (7 : 3) and the supporting electrolyte was 0.1 M Et 4 NClO 4 . All solutions were purged with N 2 before measurement. Approximately 1 mM solutions of analyte were used.
Biological assays
Cell culture. The chelators were dissolved to make 10 mM stock solutions in DMSO and diluted in medium containing 10% foetal calf serum (Commonwealth Serum Laboratories, Melbourne, Australia). A final [DMSO] < 0.5% (v/v) was used to ensure that DMSO had no effect on proliferation, 59 Fe uptake, or 59 Fe mobilisation from cells. 46 The human SK-N-MC neuroepithelioma cell line (American Type Culture Collection, Manassas, VA) was grown using standard procedures 27 in a humidified atmosphere of 5% CO 2 -95% air at 37°C in an incubator (Forma Scientific, Marietta, OH).
Effect of the chelators on cellular proliferation
The effect of the chelators on cellular proliferation was determined using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] (MTT) assay via standard methods. 27, 46 The SK-N-MC cell line was seeded at 1. The cells were then incubated in a humidified atmosphere containing 5% CO 2 and 95% air at 37°C for 72 h. Subsequently, 10 μL of MTT (5 mg mL −1 ) was added to each well and incubated at 37°C for 2 h. The cells were solubilised with 100 μL of 10% SDS-50% isobutanol in 10 mM HCl and the plates were then read at 570 nm using a scanning multi-well spectrophotometer. The inhibitory concentration (IC 50 ) was defined as the chelator concentration needed to decrease the absorbance to 50% of the untreated control. Absorbance was shown to be directly proportional to cell counts, as shown previously. Fe was removed by passage through a Sephadex G25 column and exhaustive vacuum dialysis against an excess of 0.15 mM NaCl buffered to pH 7.4 with 1.4% NaHCO 3 via standard methods. 47 
Effect of chelators on 59 Fe efflux from SK-N-MC cells
The ability of the chelators to mobilise 59 Fe from SK-N-MC cells was performed by established techniques. 46 After prelabelling cells with 59 Fe 2 -Tf (0.75 μM) for 3 h at 37°C, the cell monolayer was washed four times on ice with ice-cold PBS and subsequently incubated with the chelators (25 μM) for 3 h at 37°C. The overlying media containing released 59 Fe was separated from the cells using a Pasteur pipette. Radioactivity in the cell pellet and the supernatant was measured using a γ-scintillation counter (Wallac Wizard 3, Turku, Finland). In these studies, the novel ligands were compared to the well-characterised chelators, DFO, H 2 NIH (311) and HDp44mT. ; Sigma). 46, 47 The cells were removed using a plastic spatula and centrifuged at 14 000 rpm for 1 min. The pronase-insensitive fraction represents internalised 59 Fe, while the supernatant represents the membranebound, pronase-sensitive 59 Fe that was released by the protease. 46, 47 The ligands were compared to the previously characterised chelators, DFO, 311 and HDp44mT.
19,46
Crystallography Crystallographic data were acquired at 23°C on an Oxford Diffraction Gemini CCD diffractometer employing either Mo-Kα or Cu-Kα radiation (see Table 1 ) and operating in the ω-scan mode. Data reduction and empirical absorption corrections (multi-scan) or analytical absorption corrections were performed with Oxford Diffraction CrysAlisPro software. Structures were solved by direct methods with SHELXS and refined by full-matrix leastsquares analysis with SHELXL-97. 49 All non-H atoms were refined with anisotropic thermal parameters. Molecular structure diagrams were produced with ORTEP3. 50 All calculations were carried out within the WinGX graphical user interface. 51 In the structure of [Fe(PCSME)(PSME)]·Me 2 CO the acetone molecule was modelled as a diffuse contribution to the overall scattering without specific atom positions using SQUEEZE/PLATON. 52 Crystal and refinement data are summarised in Table 1 .
Results and discussion
Free ligand characterisation
The dithiocarbazate Schiff base ligands in Chart 2 were prepared by variations on published procedures 31, 33 involving condensation between S-methyl (or S-benzyl) thiocarbazate and the corresponding aldehyde or ketone. These Schiff base ligands This journal is © The Royal Society of Chemistry 2012 present a homologous series bearing a common NNS donor set. As a representative example, the single crystal structure of HAPSMC was determined. A view of the ligand appears in Fig. 1 . The compound adopts an approximately planar conformation. Of note is that the donor atoms (N1, N2 and S1) are not in the required conformation for tridentate coordination and 180°r otation of the C8-N3 and C5-C6 bonds are required. The C8-S1 bond has double bond character in contrast to the S-methyl single bond (S2-C9). The C8-S2 bond is slightly shorter than S2-C9 indicating some electronic delocalisation. Selected bond lengths appear in Table 2 .
Fe complexation
Deprotonation of the thioamide N atom accompanies tridentate coordination of each dithiocarbazate Schiff base ligand. The Fe complexes of these ligands were the focus of our investigation here. Given the parallels with our previous work on the HPCIH (hydrazone) 16 and HDp44mT (thiosemicarbazone) series, 28 the present set of dithiocarbazate compounds exhibit chemical and biological properties reminiscent of both. The Fe II complexes were prepared by reaction of the ligands with ferrous perchlorate in EtOH under an inert atmosphere to avoid oxidation to the trivalent state during synthesis. Each ferrous complex exhibited a characteristically green colour due to a broad and intense MLCT (Fe II → pyridine) transition around 670 nm (Fig. 2) . Similar maxima have been identified in the Fe II complexes of the HPCIH [16] [17] [18] and HDp44mT [28] [29] [30] analogues. In the solid state, the Fe II complexes are stable and do not undergo oxidation. The Fe III complexes were prepared by direct reaction with ferric perchlorate in EtOH. The ferric complexes are dark brown and exhibit a series of broad, overlapping and intense electronic transitions that span most of the visible region (Fig. 2) . The free ligands exhibit no electronic maxima in the visible region and are pale yellow in colour.
Purification of the Fe complexes was generally possible by recrystallisation, but column chromatography (silica) was sometimes necessary to separate mixtures of Fe II and Fe III complexes that co-precipitated. This is a new method for purification of these complexes and facilitated isolation of compounds for single crystal X-ray work. Table 2 Selected bond lengths and angles (ligands 'a' and 'b' defined by labels in Fig. 3 and 4) . A view of the complex cation appears in Fig. 3 . The meridional configuration of each ligand is apparent to produce a complex with approximate C 2 symmetry. The Fe-N and Fe-S bond lengths ( Table 2 ) are characteristic of low spin Fe III complexes seen in related thiosemicarbazone and thiohydrazone ferric complexes from the HDp44mT 30 and HPKTBH 27 series. There is no conformational flexibility in the complex cation except for the Smethyl groups which each adopt an anti-conformation with respect to the adjacent coordinated S-donor. The most significant variations in intraligand bond lengths (going from free ligand to complex) are in the region of the coordinated S-donors. The C8-S1 and C8-S2 bond lengths in [Fe(PCSMC) 2 ] + are identical in the complex due to electron delocalisation across the N3-C8 (S1)-S2 moiety in contrast to what is seen in the structure of the analogue HAPSMC where the C8vS1 bond has definite double bond character. The C3-N3 bonds in each ligand shorten appreciably upon complexation, defining an effective iminethiolate (-NvC-S − ) resonance form of the coordinated ligand anion. No significant variations in the N2-N3 or N2-C6 bonds are apparent on deprotonation and complexation.
The crystal structure of the homologous complex [Fe (PKSMC) 2 ] + was also determined (Fig. 4) . The geometry of the complex cation mirrors that of [Fe(PCSMC) 2 ] + . Again the coordinate bonds and angles are consistent with low spin Fe III complexes of the dithiocarbazate Schiff base ligands (Table 2) + . This may be attributed to a combination of interligand repulsion brought about by introduction of the non-coordinating pyridyl rings and also electron-withdrawing effects of these groups that may slightly weaken the donor strength of the PKSMC − ligand. Curiously, the complex [Fe(PKSMC) 2 ] + co-crystallised with a cationic pyridotriazinium derivative (MPPT + , Fig. 4) ; a byproduct of ligand desulfuration. It is not known whether Fe catalyses this reaction, although the loss of sulfide (or hydrogen sulfide) is probably assisted by the presence of free metal ions. A tentative mechanism is proposed in Scheme 1. It is known that elimination of methanethiol followed by ring closure is an alternative possibility in dithiocarbazates of this type, leading to an exocyclic thioamide (rather than thioether) group. 53 Depending on the order of addition of reagents (ligand, ferric perchlorate and base), different products were observed in the synthesis of the Fe III complex of HPCSMC. When the ferric salt was added last, an unusual mixed-ligand Fe III complex was obtained following column chromatography, namely [Fe (PCSMC)(PSMC)]. The ligand dianion PSMC 2− (Chart 2) is + cation (30% probability ellipsoids). ) where N2a formally carries a negative charge due to amide deprotonation. The extension of the Fe-S1b bond may be a consequence of Fe-N1b elongation as both donor atoms are part of the same rigid chelate ring. Another structural feature is the change in bond order of C6-N2 from a formal (imine) double bond in the dithiocarbazates ( may co-exist and interconvert. This is germane in a cellular environment due to the ability of redox-active Fe complexes to catalyse the production of hydroxyl radicals (Fenton chemistry, eqn (1)), 55 which leads to oxidative stress and damage to important biomolecules.
Previous investigations on Fe complexes of thiosemicarbazone complexes [28] [29] [30] have shown that compounds possessing Fe III/II redox potentials in the range 0 to +200 mV vs. NHE are also able to catalyse the production of hydroxyl radicals in the presence of hydrogen peroxide. For eqn (1) to be catalytic, the Fe III complex must be able to be reduced by intracellular reductants (eqn (2)) so the rate of both eqn (1) and (2) will be important in determining the overall yield of˙OH. The higher potential Fe II complexes will be less reactive toward H 2 O 2 but more easily reduced from their reactive Fe III form. Cyclic voltammetry of the Fe complexes of the dithiocarbazate ligands was undertaken and the results are summarised in Fig. 6 and Table 3 . In all cases the Fe II and Fe III dithiocarbazate complexes gave identical and totally reversible cyclic voltammograms confirming their common structural features (identical first coordination spheres). Only the voltammograms of the Fe III complexes are shown in Fig. 6 . Any differences in redox potentials are attributed to changes in inductive effects of the substituents. It is immediately apparent that altering the terminal S-substitutent (from methyl to benzyl) has little effect (ca. 10 mV) on the Fe III/II redox potential. This is to be expected given the fact that substitution of a phenyl ring with a H-atom occurs at a position remote from the metal. The substituent on atom C6 (as defined in Fig. 1 [16] [17] [18] The redox potential of the unusual mixed-ligand complex [Fe (PSMC)(PCSMC)] was much lower than the symmetric bisdithiocarbazate complexes. The voltammetry at three different sweep rates is shown in Fig. 7 Fe released in the presence of each ligand. During this assay, the chelators act as "shuttles" to mobilise 59 Fe out of the cell. As expected, the control (medium alone with no chelator) resulted in only a small amount (∼4%) of 59 Fe being released from the cell over the time course of the experiment. Positive controls were the known Fe chelators, DFO, HDp44mT and H 2 NIH (311; Chart 1). 19, 46, 47 All dithiocarbazate ligands were more effective than DFO at releasing intracellular Fe and HPCSMC was the most active of all compounds being almost as effective as HDp44mT (Fig. 8A) . Furthermore, the three S-methyl dithiocarbazates (HAPSMC, HPCSMC and HPKSMC) were more effective at mobilising intracellular 59 Fe than their corresponding S-benzyl analogues (HAPSBC, HPCSBC and HPKSBC, respectively).
During the second assay (Fig. 8B) , the ability of the chelators to inhibit 59 Fe uptake from 59 Fe 2 -Tf was assessed. All results are relative to the untreated control (i.e.
59
Fe in the presence of incubation medium alone). The results mirror those obtained with the 59 Fe efflux assay. The three S-methyl dithiocarbazates are consistently more effective at preventing 59 Fe uptake from 59 Fe 2 -Tf than the three S-benzyl chelators. Again, the novel chelators prepared in this investigation were all more active than DFO, but less effective than H 2 NIH (311) or HDp44mT (Fig. 8B) .
Potential chelators for the treatment of Fe overload disorders 1, 2 must have low toxicity as the condition will in many cases require life-long administration of the drug. 1,2 Thus, the toxicity of the chelators was examined against the same SK-N-MC neuroepithelioma cell line using DFO as a negative control and the highly potent ligand, HDp44mT, as a positive control. 19, 29, 46 The results are summarised in Table 3 , where it can be seen that the two dithiocarbazates derived from 2-pyridinecarbaldehyde exhibit no apparent cytotoxicity (>10 μM). This property, in combination with their high activity in sequestering intracellular Fe, present ideal properties for a chelator in the treatment of Fe overload. The four dithiocarbazates derived from 2-acetylpyridine and di-2-pyridyl ketone show moderate to potent anti-proliferative activity, and as such, may be problematic as useful drugs for the treatment of Fe overload. However, anti-proliferative activity can be advantageous in the treatment of cancer if a large therapeutic index (anti-proliferative activity against cancer cells relative to normal cells) can be defined, and the thiosemicarbazone relatives are an example of this. 21, 22 This aspect is the subject of a separate investigation.
Conclusions
This study has focused on the Fe coordination chemistry of a series of dithiocarbazate Schiff base ligands. Both Fe III and Fe II complexes were isolated and characterised. Cyclic voltammetry showed that all undergo totally reversible redox reactions at potentials dependent on substituent effects inherent to their parent carbonyl compound (2-acetylpyridine, di-2-pyridyl ketone or 2-pyridinecarbaldehyde). All ligands were more effective in chelating intracellular Fe relative to the clinically proven chelator DFO, and the compounds derived from 2-pyridinecarbaldehyde exhibited no marked anti-proliferative activity. The results reported here mirror the trends observed with the HPCIH, HPKIH and HAPIH hydrazones. 17 In those cases, Schiff bases derived from aldehydes (bearing a H-atom at C6) exhibited no pronounced cytotoxicity in contrast to ketone-derived Schiff bases bearing a methyl, phenyl or pyridyl group at C6 which all exhibited significant anti-proliferative efficacy against cancer cells. Exactly the same trend is seen here, suggesting that the 2-pyridinecarbaldehyde group is an ideal pharmacophore for an Fe chelator with low toxicity as seen in the HPCIH analogues. 16 
